Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 24, 2020British Journal of PharmacologyOpen Access

Bone sarcomas in the immunotherapy era

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMarie‐Françoise HeymannKSKristina SchiavoneDHDominique Heymann

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Heymann et al. (2020) studied this question.

synapsesocial.com/papers/6a87d02ef762332bf8fe802ahttps://doi.org/10.1111/bph.14999
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Oncolytic Adenovirus Δ24-RGD in Combination With Cisplatin Exerts a Potent Anti-Osteosarcoma Activity2014 · 34 citations
  2. 2Review of mifamurtide in the treatment of patients with osteosarcoma2010 · 120 citations
  3. 3Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases2008 · 35 citations
  4. 4Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates2018 · 26 citations
  5. 5Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma2015 · 1,002 citations